- Home
- » Tags
- » Nalfurafine
Top View
- Customs Tariff - Schedule
- Preclinical Testing of Nalfurafine As an Opioid-Sparing Adjuvant That Potentiates Analgesia by the Mu Opioid Receptor-Targeting Agonist Morphine*
- Report on the Deliberation Results November 6, 2008 Evaluation And
- The Κ-Opioid Receptor Agonist Nalfurafine
- The Study of Pain in Rats and Mice
- PROGRAM BOOK Table of Contents
- Investigating the Anti-Cocaine, Anti-Nociceptive Properties and Side Effects of MP1104, a Novel Mixed Opioid Receptor Agonist
- Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL
- Kappa;-Opioid Receptor Activation in Dopamine Neurons
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- Atc Index 2010
- Sex Differences in Kappa Opioid Pharmacology
- Effects of Kappa Opioid Receptor Agonists on Fentanyl Vs
- Advances in Achieving Opioid Analgesia Without Side Effects
- Annual Report 2008 Page 2/158 EMEA/330566/2009 6.4 EMEA Document Management and Publishing ______81 ANNEXES
- Annual Report 2013
- Winfuran, INN-Nalfurafine
- Nalfurafine Hydrochloride, a Selective Κ Opioid
- Preclinical Testing of Nalfurafine As an Opioid-Sparing Adjuvant That Potentiates Analgesia by the Mu Opioid Receptor-Targeting Agonist Morphine*
- Pharmaceuticals and Medical Devices Safety Information No
- Nalfurafine* 0.36 0.71 49.9 in a Dose-Dependent Manner, with a Duration of Action of –– the Separation from Placebo-Treated Patients in Worst Itch Table 3
- ( 12 ) United States Patent
- Strategies for Developing Kappa Opioid Receptor Agonists for the Treatment of Pain with Fewer Side-Effects
- The Pharmaceuticals and Medical Devices Agency Annual Report Fy 2008 Table of Contents
- Inan Temple 0225E 10333.Pdf
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Pharmaceuticals and Medical Devices Safety Information No
- NDSP Catalog 23Rd Edition
- Nalfurafine Hydrochloride for Refractory Pruritus in Peritoneal Dialysis Patients
- I. Development of Bisamides As Kappa Opioid Receptor Agonists. II
- 3Rd Conference on the “Therapeutic Potential of Kappa Opioids” Monday, April 20Th Tuesday, April 21St
- 1 Dose-Dependent Naloxone-Induced Morphine Withdrawal Symptoms in Opioid-Dependent Males - a Double-Blinded, Randomized Study
- ― D04 - 1 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版( 2019) カテゴリー別リスト
- Meeting Program
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Nalbuphine Attenuates Itch in the Substance P-Induced Mouse Model
- International Nonproprietary Names
- Uraemic Pruritus
- Signal Detection of Oral Drug-Induced Dementia in Chronic Kidney Disease Patients Using Association Rule Mining and Bayesian Confidence Propagation Neural Network
- Report on the Deliberation Results November 26, 2014 Evaluation And
- Spinal Kappa Opioid Receptor Activity Inhibits Adenylyl Cyclase-1 Dependent Mechanisms of Chronic Postoperative Pain
- In Vitro and in Vivo Profile of Ppl-101 and Ppl-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential
- Newsletter Issue 11, 2021 As EBPS Members, We Have Two Exciting Events to Look Forward to in 2021, Information About Which Can Also Be Found Here
- Opioid System in Uremic Pruritus: Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Studies
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Ckd-Associated Pruritus
- P36885 Cara Therapeutics, Inc. 10K 2020 V1
- Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT